The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Extracellular Matrices (I); Roche
Stock and Other Ownership Interests - Roche
Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.
 
Gloria S. Huang
Honoraria - AstraZeneca
 
Melissa A. Merritt
No Relationships to Disclose
 
Alan Hutson
No Relationships to Disclose
 
Howard D. Strickler
No Relationships to Disclose
 
Mark Einstein
No Relationships to Disclose
 
Jurriaan Brouwer-Visser
No Relationships to Disclose
 
Nilsa C. Ramirez
No Relationships to Disclose
 
Heather A. Lankes
No Relationships to Disclose
 
Mona El-Bahrawy
No Relationships to Disclose
 
Xiaonan Xue
No Relationships to Disclose
 
Herbert Yu
No Relationships to Disclose
 
Robert S. Mannel
Consulting or Advisory Role - Clovis Oncology (Inst); Tesaro (Inst); Tesaro (Inst)
 
David M. O'Malley
Honoraria - Abbvie; Ambry Genetics; AstraZeneca; BioMedical Insights; Clovis Oncology; Genentech/Roche; GOG Foundation; Immunogen; Janssen Oncology; Marker Therapeutics; Myriad Genetics; Novocure; OncLive; OncoQuest; Prime Oncology; Targeted Oncology; Tesaro; Translational Genomics Research Institute
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Clovis Oncology; Genentech/Roche; GOG Foundation; Immunogen; Janssen Oncology; Myriad Genetics; Novocure; OncoQuest; Tesaro; Translational Genomics Research Institute
Research Funding - Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Janssen Research & Development (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Stem CentRx (Inst); Tesaro (Inst); TRACON Pharma (Inst); VentiRx (Inst)
 
David Gardner Mutch
Honoraria - Clovis Oncology
Consulting or Advisory Role - lilly
Speakers' Bureau - AstraZeneca
 
Paul Disilvestro
Consulting or Advisory Role - AstraZeneca; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen Oncology (Inst); Tesaro (Inst)
Expert Testimony - Johnson & Johnson
 
Melissa Ann Geller
Speakers' Bureau - Tesaro
Research Funding - Bayer; FATE Therapeutics; Genentech; Morphotek; Ovagene Oncology; Tesaro
 
Saketh R Guntupalli
Consulting or Advisory Role - Clovis Oncology; Tesaro
Research Funding - Bristol-Myers Squibb
 
Michael J. Birrer
Consulting or Advisory Role - Acceleron Pharma; AstraZeneca; Clovis Oncology; Immunogen; Immunogen; Merrimack; Oxigene; Roche/Genentech; Sanofi; Tesaro; Threshold Pharmaceuticals
 
David S. Miller
Consulting or Advisory Role - Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Immunogen (Inst); Janssen (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Pfizer (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Marc J. Gunter
No Relationships to Disclose